Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives

Journal of Medicinal Chemistry

Volumn 50, Issue 22, 2007, Pages 5364-5371

  Carotti, Andrea ^a   Catto, Marco ^a   Leonetti, Francesco ^a   Campagna, Francesco ^a   Soto Otero, Ramón ^b   Méndez Álvarez, Estefanía ^b   Thull, Ulrike ^c   Testa, Bernard ^c,d   Altomare, Cosimo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIAZINE DERIVATIVE; 3 (3 NITROPHENYL) 9H INDENO[1,2 E][1,2,4]TRIAZIN 9 ONE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BROFAROMINE; CLORGYLINE; LAZABEMIDE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; PHENOXYMETHYL DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SELEGILINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SYNTHESIS; IC 50; IN VITRO STUDY; INHIBITION KINETICS; ISOMERISM; MOLECULAR MODEL; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; BRAIN; HETEROCYCLIC COMPOUNDS, 3-RING; ISOENZYMES; MITOCHONDRIA; MODELS, MOLECULAR; MONOAMINE OXIDASE INHIBITORS; PYRIDAZINES; PYRIMIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; TRIAZINES;

EID: 35848930607     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070728r     Document Type: Article

References (52)

1. Tipton, K. F. Enzymology of monoamine oxidase. Cell Biochem. Funct. 1986, 4, 79-87.
2. Nagatsu, T. Progress in monoamine oxidase (MAO) research in relation to genetic engineering. Neurotoxicology 2004, 25, 11-20.
3. Shih, J. C. Cloning, after cloning, knock-out mice, and physiological functions of MAO-A and B. Neurotoxicology 2004, 25, 21-30.
4. Testa, B.; Krämer, S. D. The biochemistry of drug metabolism - An introduction. Part 2: Redox reactions and their enzymes. Chem. Biodiv. 2007, 4, 257-405.
5. Bach, A. W.; Lan, N. C.; Johnson, D. L.; Abell, C. W.; Bembenek, M. E.; Kwan, S. W.; Seeburg, P. H.; Shih, J. C. cDNA cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4934-4938.
6. Kwan, S. W.; Abell, C. W. cDNA cloning and sequencing of rat monoamine oxidase A: comparison with the human and bovine enzymes. Comp. Biochem. Physiol. B 1992, 102, 143-147.
7. Kalgutkar, A. S.; Castagnoli, N., Jr.; Testa, B. Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism. Med. Res. Rev. 1995, 15, 325-388.
8. Grimsby, J.; Lan, N. C.; Neve, R.; Chen, K.; Shih, J. C. Tissue distribution of human monoamine oxidase A and B mRNA. J. Neurochem. 1990, 55, 1166-1669.
9. Riederer, P.; Lachenmayer, L.; Laux, G. Clinical applications of MAO-inhibitors. Curr. Med. Chem. 2004, 11, 2033-2043.
10. Yamada, M.; Yasuhara, H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology 2004, 25, 215-221.
11. Palhagen, S.; Heinonen, E.; Hägglund, J.; Kaugesaar, T.; Mäki-Ikola, O.; Palm, R. Selegiline slows the progression of symptoms of Parkinson disease. Neurology 2006, 66, 1200-1206.
12. Riederer, P.; Danielczyk, W.; Grunblatt, E. Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology 2004, 25, 271-277.
13. Youdim, M. B. H.; Fridkin, M.; Zheng, H. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J. Neural Transm. 2004, 3, 205-214.
14. Wouters, J. Structural aspects of monoamine oxidase and its reversible inhibition. Curr. Med. Chem. 1998, 5, 137-162.
15. Shih, J. C.; Chen, K.; Geha, R. M. Determination of regions important for monoamine oxidase (MAO) A and B substrate and inhibitor selectivities. J. Neural. Transm. Suppl. 1998, 52, 1-8.
16. Gottowik, J.; Malherbe, P.; Lang, G.; Da Prada, M.; Cesura, A. M. Structure/function relationships of mitochondrial monoamine oxidase A and B chimeric forms. Eur. J. Biochem. 1995, 230, 934-942.
17. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D. E.; Mattevi, A. Three-dimensional structure of human monoamine oxidase A (MAO-A): Relation to the structures of rat MAO-A and human MAO-B. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 12684-12689.
18. Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D. E.; Mattevi, A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol. 2002, 9, 22-26.
19. Binda, C.; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmondson, D. E.; Mattevi, A. Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindane class. J. Med. Chem. 2004, 47, 1767-1774.
20. Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D. E.; Mattevi, A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 9750-9755.
21. Edmondson, D. E.; Mattevi, A.; Binda, C.; Li, M.; Hubalek, F. Structure and mechanism of monoamine oxidase. Curr. Med. Chem. 2004, 11, 1983-1993.
22. Carrieri, A.; Carotti, A.; Barreca, M. L.; Altomare, C. Binding models of reversible inhibitors to type-B monoamine oxidase. J. Comput.-Aided Mol. Des. 2002, 16, 769-778.
23. Novaroli, L.; Daina, A.; Favre, E.; Bravo, J.; Carotti, A.; Leonetti, F.; Catto, M.; Carrupt, P.-A.; Reist, M. Impact of species-dependent differences on screening, design, and development of MAO-B inhibitors. J. Med. Chem. 2006, 49, 6264-6272.
24. Kneubühler, S.; Carta, V.; Altomare, C.; Carotti, A.; Testa, B. Synthesis and monoamine oxidase inhibitory activity of 3-substituted 5H-indeno[1,2-c]pyridazines. Helv. Chim. Acta 1993, 76, 1954-1963.
25. Kneubühler, S.; Thull, U.; Altomare, C.; Carta, V.; Gaillard, P.; Carrupt, P.-A.; Carotti, A.; Testa, B. Inhibition of monoamine oxidase-B by 5H-indeno[1,2-c]pyridazines: biological activities, quantitative structure-activity relationships (QSARs) and 3D-QSARs. J. Med. Chem. 1995, 38, 3874-3883.
26. Thull, U.; Kneubühler, S.; Gaillard, P.; Carrupt, P.-A.; Testa, B.; Altomare, C.; Carotti, A.; Jenner, P.; McNaught, K. St. P. Inhibition of monamine oxidase by isoquinoline derivatives: qualitative and 3D-quantitative structure-activity relationships. Biochem. Pharmacol. 1995, 50, 869-877.
27. Altomare, C.; Cellamare, S.; Summo, L.; Catto, M.; Carotti, A.; Thull, U.; Carrupt, P.-A.; Testa, B.; Stoekli-Evans, H. Inhibition of monoamine oxidase-B by condensed pyridazines and pyrimidines; effects of lipophilicity and structure-activity relationships. J. Med. Chem. 1998, 41, 3812-3820.
28. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.-A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. J. Med. Chem. 2000, 43, 4747-4758.
29. Carotti, A.; Carrieri, A.; Chimichi, S.; Boccalini, M.; Cosimelli, S.; Gnerre, C.; Carotti, A.; Carrupt, P.-A., Testa, B. Natural and synthetic geiparvarins are strong and selective MAO-B inhibitors. Synthesis and SAR studies. Bioorg. Med. Chem. Lett. 2002, 12, 3551-3555.
30. Novaroli, L.; Reist, M.; Favre, E.; Carotti, A.; Catto, M.; Carrupt, P.-A. Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening. Bioorg. Med. Chem. 2005, 13, 6212-6217.
31. Carotti, A.; Altomare, C.; Catto, M.; Gnerre, C.; Summo, L.; De Marco, A.; Rose, S.; Jenner, P.; Testa, B. Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7-substituted coumarins. Chem. Biodiv. 2006, 3, 134-149.
32. Catto, M.; Nicolotti, O.; Leonetti, F.; Favia, A. D.; Soto-Otero, R.; Méndez-Alvarez, E.; Carotti, A. Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches. J. Med. Chem. 2006, 49, 4912-4925.
33. Ooms, F.; Frederick, R.; Durant, F.; Petzer, J. P.; Castagnoli, N., Jr.; Van der Schyf, J.; Wouters, J. Rational approaches towards reversible inhibition of type B monoamine oxidase. Design and evaluation of a novel 5H-indeno[1,2-c]pyridazin-5-one derivative. Bioorg. Med. Chem. Lett. 2003, 12, 69-73.
34. Frédérick, R.; Dumont, W.; Ooms, F.; Aschenbach, L.; Van der Schyf, J.; Castagnoli, N.; Wouters, J.; Krief, A. Synthesis, structural reassignment, and biological activity of type B inhibitors based on the 5H-indeno[1,2-c]pyridazin-5-one core. J. Med. Chem. 2006, 49, 3743-3747.
35. Cignarella, G.; Loriga, M.; Pinna, G. A.; Pirisi, M. A.; Schiatti, P.; Selva, D. Unexpected anti-inflammatory activity of rigid structures derived from antihypertensive 6-arylpyridazinones. III. Synthesis and activity of 7-fluoro- and 5-keto-5H-indeno[1,2-c]pyridazines. Farmaco 1982, 37, 133-144.
36. Heinish, G.; Jentzsch, A.; Pailer, M. C-4 substituted pyridazines by homolitic alkylation and acylation. Monatsh. Chem. 1974, 105, 648-652.
37. Case, F. H. The action of diphenyl triketone and of ninhydrin on certain carboxamide hydrazones. J. Heterocycl. Chem. 1972, 9, 457-458.
38. Campagna, F.; Palluotto, F.; Mascia, M. P.; Ma ciocco, E.; Marra, C.; Carotti, A.; Carrieri, A. Synthesis and biological evaluation of pyridazino[4,3-b]indoles and indeno[1,2-c]pyridazines as new ligands of central and peripheral benzodiazepine receptors. Farmaco 2003, 58, 129-140.
39. Ghigi, E. Su alcuni omologhi nucleari del carbazolo idrogenato e derivati pirazolonici dell'a-tetralone (On some nuclear homologues of hydrogenated carbazole and pyrazolone derivatives of a-tetralone). Gazz. Chim. Ital. 1930, 60, 194-199.
40. Pappa, H.; Segall, A.; Pizzorno, M. T.; Radice, M.; Amoroso, A.; Gutkind, G. O. Antimicrobial activity of 5,6-dihydrobenzo[a]carbazoles. Farmaco 1994, 49, 333-336.
41. Medvedev, A. E.; Veselovsky, A. V.; Shvedov, V. I.; Tikhonova, O. V.; Moskvitina, T. A.; Fedotova, O. A.; Axenova, L. N.; Kamyshanskaya, N. S.; Kirkel, A. Z.; Ivanov, A. S. Inhibition of monoamine oxidase by pirlindole analogues: 3D-QSAR and CoMFA analysis. J. Chem. Inf. Comput. Sci. 1998, 38, 1137-1144.
42. Altomare, C.; Carrupt, P.-A.; Gaillard, P.; El Tayar, N.; Testa, B.; Carotti, A. Quantitative structure-metabolism relationship analyses of MAO-mediated toxication of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and analogues. Chem. Res. Toxicol. 1992, 5, 366-375.
43. 50 < 10 μM) have log P values ranging from 2.44 (2a) to 3.57 (4a).
44. -1, Polak-Ribiere conjugate gradient). The ligand-free protein and cofactor were kept rigid, except for the side chains of the residues lying within a distance of 4 Å from 1,4-diphenyl-2-butene in the original pdb complex (1oj9) retrieved by the Brookhaven Protein Data Bank (http://www.rcsb.org/pdb/), which were settled free to relax during the minimization of the binding complexes found by the calculation routine. Finally, phenol oxygen atom of Y398 was marked for indicating the binding cavity, and the inhibitor added and settled as completely free to move. To allow a good sampling of the conformational space, 1000 runs of Monte Carlo search, followed by conjugate gradient minimization, were performed, and the first-scored 25 low-energy docking hypotheses were taken into account.
45. Warren, L. The PyMOL Molecular Graphics System, DeLano Scientific LLC, San Carlos, CA; http://www.pymol.org.
46. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins: Struct., Funct., Genet. 2003, 52, 609-623.
47. Gaillard, P.; Carrupt, P.-A.; Testa, B.; Boudon, A. Molecular lipophilicity potential, a tool in 3D-QSAR. Method and applications. J. Comput-Aided Mol. Des. 1994, 8, 83-96.
48. Hynson, R. M. G.; Wouters, J.; Ramsay, R. R. Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure. Biochem. Pharmacol. 2003, 65, 1867-1874.
49. Imamoto, T.; Takiyama, N.; Nakamura, K. Cerium chloridepromoted nucleophilic addition of Grignard reagents to ketones. An efficient method for the synthesis of tertiary alcohols. Tetrahedron Lett. 1985, 26, 4763-4766.
50. Clark, J. B.; Nicklas, W. J. The metabolism of rat brain mitochondria. J. Biol. Chem. 1970, 245, 4724-4731.
51. Weissbach, H.; Smith, T. E.; Daly, J. W.; Witkop, B.; Udenfriend, S. A rapid spectrophotometric assay of monoamine oxidase based on the rate of disappearance of kynuramine. J. Biol. Chem. 1960, 235, 1160-1163.
52. Thull, U.; Kneubühler, S.; Testa, B.; Borges, M. F. M.; Pinto, M. M. M. Substituted xanthones as selective and reversible monoamine oxidase A (MAO-A) inhibitors. Pharm. Res. 1993, 10, 1187-1190.